Newsadmin2020-07-22T00:29:58-04:00

News

Source: NASDAQ

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Published on 2021-02-25
EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
Published on 2021-02-25
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
Published on 2021-02-04
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Published on 2021-02-01
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Published on 2021-02-01
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
Published on 2021-01-28
EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
Published on 2021-01-11
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
Published on 2021-01-03
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation
Published on 2020-12-18
EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Published on 2020-12-08
EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
Published on 2020-12-03
EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
Published on 2020-11-19
EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
Published on 2020-11-16
EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
Published on 2020-11-10
EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Published on 2020-11-05
EyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information
Published on 2020-10-29
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants
Published on 2020-10-08
EyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020
Published on 2020-10-07
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Published on 2020-09-10
EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®
Published on 2020-08-24